Stock Movers

On this episode of Stock Movers:
- KB Home (KBH) shares fell after the single-family home builder reported forecast deliveries for the second quarter that missed the average analyst estimate.
- Sarepta Therapeutics (SRPT) shares jump after the biotech released early clinical data from its siRNA pipeline. Oppenheimer (outperform) analyst Kostas Biliouris says “early DM1/FSHD data appear promising, but full dataset & more markers needed for conclusions”
- ARM (ARM) shares rise after news it will sell its own chips for the first time, with Meta Platforms Inc. as the first major customer, and expects to generate about $15 billion annually within five years. The company's new chip, called an AGI CPU, will have as many as 136 cores and draw 300 watts of electricity, and will be produced by Taiwan Semiconductor Manufacturing Co.
See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- ARM (ARM) shares rise after news it will sell its own chips for the first time, with Meta Platforms Inc. as the first major customer, and expects to generate about $15 billion annually within five years. The company's new chip, called an AGI CPU, will have as many as 136 cores and draw 300 watts of electricity, and will be produced by Taiwan Semiconductor Manufacturing Co.
- Chewy (CHWY) shares gain after the online retailer of pet products gave a net sales forecast for the fiscal year 2027 that beat the average analyst estimate. This suggests the online pet retailer expects strong demand to more than make up for headwinds including inflation and tariff uncertainty.
- Echostar (SATS) shares are up. EchoStar, Rocket Lab and AST SpaceMobile rally on Wednesday as the Information reports that SpaceX aims to file a prospectus for an initial public offering as soon as this week.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Merck (MRK) agreed to buy Terns Pharmaceuticals Inc. for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its bestselling cancer drug.
- The Pentagon has agreed with major defense contractors on a series of framework agreements meant to accelerate production of key missile systems that have seen heavy use during the initial phases of the US and Israeli war against Iran. Lockheed Martin and BAE Systems agreed with the Defense Department on plans to “quadruple the production of seekers for the Terminal High Altitude Area Defense (THAAD) interceptor,” according to a Pentagon announcement.
- Chewy (CHWY) shares rise after the online retailer of pet products gave a net sales forecast for the fiscal year 2027 that beat the average analyst estimate.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Merck & Co (MRK) to buy Terns Pharmaceuticals (TERN) for $53/share in cash for an approximate equity value of $6.7 billion.
- Shares of Arm Holdings (ARM), which made its name licensing technology to semiconductor makers, rose in premarket trading after it said it will sell its own chips for the first time, in a move forecast to generate about $15 billion annually within five years.
- Braze shares rise after the software company forecast revenue for the first quarter that was higher than the average analyst estimate.
See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- KB Home (KBH) shares are down 5% in postmarket trading Tuesday after the single-family home builder reported forecast deliveries for the second quarter that missed the average analyst estimate.

- Arm Holdings (ARM) which made its name licensing technology to semiconductor makers, will begin selling its own chips for the first time, adding a business that it expects to generate about $15 billion annually within five years. Shares closed down 1.41%.

- ImmunityBio (IBRX)shares plunged after the biotechnology company and its billionaire executive chairman, Patrick Soon-Shiong, were hit with a Food and Drug Administration warning letter for false and misleading promotion of its bladder cancer drug Anktiva.
See omnystudio.com/listener for privacy information.